Philadelphia-negative chronic myeloproliferative neoplasms

Revista Brasileira de Hematologia e Hemoterapia

Volumn 34, Issue 2, 2012, Pages 140-149

  Bittencourt, Rosane Isabel ^a   Vassallo, Jose ^b   Chauffaille, Maria de Lourdes Lopes Ferrari ^c   Xavier, Sandra Guerra ^d   Pagnano, Katia Borgia ^b   Nascimento, Ana Clara Kneese ^e   de Souza, Carmino Antonio ^b   Chiattone, Carlos Sergio ^e  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis; Thrombocytosis

Indexed keywords

EID: 84861448274     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20120034     Document Type: Review

References (59)

1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82. Comment in: J Clin Oncol. 2011;29(18):e564-5.
2. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myeloscrerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975; 12(4):409-32.
3. Vardiman JW, Harris NL, Brunning R. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. Comment in: Blood. 2003;101(7):2895-6.
4. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22. Comment in: Leukemia. 2008;22(11):2118-9.
5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114 (5):937-51. Comment in: Blood. 2010;115(3):748-9; author reply 749-50.
6. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-32.
7. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol. 2005;20(2):633-44.
8. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4(1):33-40.
9. Ahmed A, Chang CC. Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis and prognosis. Arch Pathol Lab Med. 2006;130(8):1133-43.
10. Chauffaille ML. Neoplasias mieloproliferativas: revisão dos critérios diagnósticos e dos aspectos clínicos. Rev Bras Hematol Hemoter. 2010;32(4):308-16.
11. Maciel JF, de Lourdes Chauffaille M, Inaoka RJ, Colleoni GW, Yamamoto M. Essential Thrombocythemia after treatment of non-Hodgkin's Lymphoma. Leuk Res. 2007;31(11):1593-5.
12. Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009;83(1):17-21.
13. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. Erratum in: Lancet. 2005;366(9480):122.
14. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673-83.
15. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T; Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007; 110(12):4030-6.
16. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on use and interpretation of monitoring methods. Blood. 2008;111 (4):1774-80.
17. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477-83.
18. Tefferi A, Lasho TL, Huang J, Finke C, Hanson CA, Mesa RA, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756-61.
19. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-38.
20. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-7. Comment in: Blood. 2008;111(3): 1741; author reply 1742.
21. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hematost 2006;32(3):171-3.
22. Giuglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-91.
23. Girodon F, Bonicelli G, Schaffer C, Mounier M, Carillo S, Lafon I, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009;94(6):865-9.
24. Harrison CN, Bareford D, Butt N, Campbel P, Conneally E, Drummond M, Erber W, Everington T, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010:352-75.
25. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009; 124(4):409-17.
26. Biergegard G. Long-term management of thombocytosis in essential thrombocythaemia. Ann Hematol. 2009;88(1):1-10.
27. Landolfi R, Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93(3): 331-5. Comment on: Haematologica. 2008;93(3):372-80.
28. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood. 2003;101(9):3749. Comment on: Blood. 2001;97(4):863-6.
29. Beer P, Erber W, Campbell P, Green A. How I treat essential thrombocythemia. Blood. 2011;117(5):1472-82. Comment in: Blood. 2011;118(4):1179-80; author reply 1180-1.
30. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.Biol Blood Marrow Transplant. 2007; 13(3):355-65.
31. Spivak J. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 2010;152(5):300-6.
32. Swerdlow SH, International Agency for Research on Cancer., World Health Organization., Louis A. Duhring Fund.: WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
33. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29 (10):1356-63.
34. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-8.
35. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113 (13):2895-901. Comment in: Blood. 2010;115(3):745; author reply 745-6.
36. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857-8.
37. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85(1):14-7. Comment in: Am J Hematol. 2010;85(1):4-5.
38. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-8.
39. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361-70.
40. Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev. 1999;13(3):163-70.
41. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358-67.
42. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. Comment in: N Engl J Med. 2010; 363(12): 1180-2; N Engl J Med. 2010;363(25):2464; author reply 2464-5; discussion 2465.
43. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-96. J Clin Oncol. 2011;29(7):781-3.
44. Vaquez H. Sur une forme spéciale de cyanose s'accompgnant d'hyperglobulie excessive et persistant. Comptes rendus de La Société de Biologie, Paris, 1892;44:384-88.
45. Osler W. Chronic cyanosis with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci. 2008;335(6):411-7. Comment in: Am J Med Sci. 2008;335(6):418-9.
46. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-51.
47. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90. Comment in: N Engl J Med. 2005;353(13):1416-7; author reply 1416-7; N Engl J Med. 2005;352(17):1744-6.
48. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2(V617F) mutation status, granulocyte activation and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-82.
49. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic eritrocytosis. N Engl J Med. 2007;356(5):459-68. Comment in: N Engl J Med. 2007;356(5):444-5.
50. McMullin M, Reilly JT, Campbell P, Bareford D, Green A, Harrison C. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007;138:812-23.
51. Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and nonalkylating drugs. Ann Hematol. 2010;89(7):691-9.
52. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759-63.
53. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-33.
54. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia-Negative Classical Myeloproliferative Neoplass: Critical Concepts and Management Recommendations from European Leukemianet. J Clin Oncol. 2011;29(6):761-70. Comment in: J Clin Oncol. 2011;29(18):e564-5.
55. Rambaldi A, Dellacasa CM, Salmoiraghi S, et al. A phase 2 A study of the histone-deacetylase inhibitor in patients with JAK2V617F positive myeloproliferative neoplasms. {abstract}. Blood 2008;112:100. (não localizada)
56. Chauffaille, MLLF. Neoplasias mieloproliferativas: revisão dos critérios diagnósticos e dos aspectos clínicos. Rev Bras Hematol. Hemoter. 2010;32(4);308-16.
57. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopatic. Br J Haematol. 2006;133(5):468-92.
58. Fletcher S, Bain B. Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol. 2007;14(1):37-42.
59. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4): 946-56.